Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
Jane Merlevede, Nathalie Droin, Tingting Qin, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 201

Showing 1-25 of 201 citing articles:

The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov, Jaegil Kim, Nicholas J. Haradhvala, et al.
Nature (2020) Vol. 578, Iss. 7793, pp. 94-101
Open Access | Times Cited: 2870
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen, Jeremy Travins, Fang Wang, et al.
Cancer Discovery (2017) Vol. 7, Iss. 5, pp. 478-493
Open Access | Times Cited: 399
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima, Tetsuichi Yoshizato, Kenichi Yoshida, et al.
Nature Genetics (2016) Vol. 49, Iss. 2, pp. 204-212
Open Access | Times Cited: 382
Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors
Nathaniel D. Anderson, Richard de Borja, Matthew D. Young, et al.
Science (2018) Vol. 361, Iss. 6405
Open Access | Times Cited: 163
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Julia Stomper, John Charles Rotondo, Gabriele Greve, et al.
Leukemia (2021) Vol. 35, Iss. 7, pp. 1873-1889
Open Access | Times Cited: 151
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2228-2247
Open Access | Times Cited: 143
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2022) Vol. 97, Iss. 3, pp. 352-372
Closed Access | Times Cited: 72
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 6, pp. 1142-1165
Open Access | Times Cited: 24
A mutant ASXL1-BAP1-EHMT complex contributes to heterochromatin dysfunction in clonal hematopoiesis and chronic monomyelocytic leukemia
Zhen Dong, Hugo Sepúlveda, Leo J. Arteaga-Vazquez, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 1
Closed Access | Times Cited: 2
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Jeannine Diesch, Anabel Zwick, Anne-Kathrin Garz, et al.
Clinical Epigenetics (2016) Vol. 8, Iss. 1
Open Access | Times Cited: 152
The Repertoire of Mutational Signatures in Human Cancer
Ludmil B. Alexandrov, Jaegil Kim, Nicholas J. Haradhvala, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2018)
Open Access | Times Cited: 143
Clonal evolution in myelodysplastic syndromes
Pedro da Silva-Coelho, Leonie I. Kroeze, Kenichi Yoshida, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 138
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Shaima’a Hamarsheh, Lena Oßwald, Benedikt S. Saller, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 124
Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2019) Vol. 95, Iss. 1, pp. 97-115
Open Access | Times Cited: 119
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2018) Vol. 93, Iss. 6, pp. 824-840
Open Access | Times Cited: 111
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
Ashwin Unnikrishnan, Elli Papaemmanuil, Dominik Beck, et al.
Cell Reports (2017) Vol. 20, Iss. 3, pp. 572-585
Open Access | Times Cited: 110
Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
Khushboo Agrawal, Viswanath Das, Pankhuri Vyas, et al.
Pharmacology & Therapeutics (2018) Vol. 188, pp. 45-79
Open Access | Times Cited: 109
How I treat chronic myelomonocytic leukemia
Éric Solary, Raphaël Itzykson
Blood (2017) Vol. 130, Iss. 2, pp. 126-136
Open Access | Times Cited: 106
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
Raphaël Itzykson, Pierre Fenaux, David Bowen, et al.
HemaSphere (2018) Vol. 2, Iss. 6
Open Access | Times Cited: 103
Understanding mutagenesis through delineation of mutational signatures in human cancer
Mia Petljak, Ludmil B. Alexandrov
Carcinogenesis (2016) Vol. 37, Iss. 6, pp. 531-540
Open Access | Times Cited: 100
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
Geoffrey L. Uy, Eric J. Duncavage, Gue Su Chang, et al.
Leukemia (2016) Vol. 31, Iss. 4, pp. 872-881
Open Access | Times Cited: 100
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients
Giacomo Coltro, Abhishek A. Mangaonkar, Terra L. Lasho, et al.
Leukemia (2019) Vol. 34, Iss. 5, pp. 1407-1421
Closed Access | Times Cited: 84
MDS overlap disorders and diagnostic boundaries
Tiffany Tanaka, Rafael Bejar
Blood (2019) Vol. 133, Iss. 10, pp. 1086-1095
Open Access | Times Cited: 80
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Nolwenn Lucas, Matthieu Duchmann, Philippe Rameau, et al.
Leukemia (2019) Vol. 33, Iss. 10, pp. 2466-2480
Closed Access | Times Cited: 80
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Ryan M. Carr, Denis Vorobyev, Terra L. Lasho, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top